Betahistine intranasal - Otifex Therapeutics

Drug Profile

Betahistine intranasal - Otifex Therapeutics

Alternative Names: Betahistine dihydrochloride nasal spray

Latest Information Update: 28 Jun 2016

Price : $50

At a glance

  • Originator University of Melbourne
  • Developer Otifex Therapeutics
  • Class Pyridines; Small molecules
  • Mechanism of Action Histamine H1 receptor agonists; Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Otitis

Most Recent Events

  • 22 Apr 2015 Otifex Therapeutics initiates enrolment in a phase Ib trial for Otitis (In volunteers) in Australia (ACTRN12615000657527)
  • 10 Feb 2015 Otifex Therapeutics completes a phase Ia trial in Otitis (In volunteers) in Australia
  • 25 Aug 2013 Phase-I clinical trials in Otitis (In volunteers) in Australia (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top